OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $47.4750 -0.27 (-0.57 %) (As of 03/25/2019 04:00 PM ET)Previous Close$47.75Today's Range$47.11 - $47.6452-Week Range$40.38 - $55.84Volume8,742 shsAverage Volume42,952 shsMarket Capitalization$14.10 billionP/E Ratio27.13Dividend Yield1.05%Beta0.84 ProfileDiscussionAnalyst RatingsChartDividendEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Receive NVZMY News and Ratings via Email Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorBasic Materials Current SymbolOTCMKTS:NVZMY Previous Symbol CUSIPN/A CIKN/A Webwww.novozymes.com Phone45-4446-0000Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio0.74Price-To-Earnings Trailing P/E Ratio27.13 Forward P/E Ratio26.97 P/E Growth2.37 Sales & Book Value Annual Sales$2.28 billion Price / Sales6.18 Cash Flow$1.8743 per share Price / Cash Flow25.33 Book Value$6.81 per share Price / Book6.97Profitability EPS (Most Recent Fiscal Year)$1.75 Net Income$511.29 million Net Margins22.14% Return on Equity29.64% Return on Assets16.60%Miscellaneous Employees6,245 Outstanding Shares297,000,000Market Cap$14.10 billion Next Earnings Date4/24/2019 (Estimated) OptionableNot Optionable NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions What is NOVOZYMES A/S/S's stock symbol? NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY." How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S? NOVOZYMES A/S/S announced an annual dividend on Thursday, February 7th. Stockholders of record on Friday, March 1st will be paid a dividend of $0.504 per share on Tuesday, March 19th. This represents a dividend yield of 1.16%. The ex-dividend date is Thursday, February 28th. View NOVOZYMES A/S/S's Dividend History. How were NOVOZYMES A/S/S's earnings last quarter? NOVOZYMES A/S/S (OTCMKTS:NVZMY) released its quarterly earnings data on Thursday, January, 24th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.42 by $0.02. The biotechnology company earned $567.89 million during the quarter. NOVOZYMES A/S/S had a return on equity of 29.64% and a net margin of 22.14%. View NOVOZYMES A/S/S's Earnings History. When is NOVOZYMES A/S/S's next earnings date? NOVOZYMES A/S/S is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for NOVOZYMES A/S/S. What is the consensus analysts' recommendation for NOVOZYMES A/S/S? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NOVOZYMES A/S/S. Has NOVOZYMES A/S/S been receiving favorable news coverage? Media coverage about NVZMY stock has been trending somewhat negative on Monday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NOVOZYMES A/S/S earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of NOVOZYMES A/S/S's key competitors? Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO) and Aerie Pharmaceuticals (AERI). What other stocks do shareholders of NOVOZYMES A/S/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other NOVOZYMES A/S/S investors own include Novo Nordisk A/S (NVO), Zayo Group (ZAYO), Check Point Software Technologies (CHKP), Level One Bancorp (LEVL), Emerson Electric (EMR), Altria Group (MO), Duke Energy (DUK), Anadarko Petroleum (APC), Genmab A/S (GNMSF) and Twenty-First Century Fox (FOXA). Who are NOVOZYMES A/S/S's key executives? NOVOZYMES A/S/S's management team includes the folowing people: Mr. Peder Holk Nielsen, Pres & CEO (Age 63)Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46) How do I buy shares of NOVOZYMES A/S/S? Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NOVOZYMES A/S/S's stock price today? One share of NVZMY stock can currently be purchased for approximately $47.4750. How big of a company is NOVOZYMES A/S/S? NOVOZYMES A/S/S has a market capitalization of $14.10 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511.29 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,245 workers across the globe. What is NOVOZYMES A/S/S's official website? The official website for NOVOZYMES A/S/S is http://www.novozymes.com. How can I contact NOVOZYMES A/S/S? NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected] MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)Community Ranking: 1.6 out of 5 ()Outperform Votes: 74 (Vote Outperform)Underperform Votes: 154 (Vote Underperform)Total Votes: 228MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: Is a Roth IRA right for you?